CPRX
NASDAQCatalyst Pharmaceuticals Inc.
Price$31.49+5.90 (+23.06%)
2026-04-092026-07-14
News · 26 weeks67+1300%
2026-01-182026-07-12
Mix5890d
- SEC Filings27(47%)
- Insider15(26%)
- Other12(21%)
- Earnings3(5%)
- Leadership1(2%)
Latest news
25 items- INSIDERChief HR Officer Russo Gregg returned $14,994 worth of shares to the company (476 units at $31.50), closing all direct ownership in the company (SEC Form 4) (withholding tax)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Legal Officer Elsbernd Brian returned $7,638,782 worth of shares to the company (242,501 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERSEC Form 4 filed by Director Curran Daniel J. to cover taxes4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Thompson Tamar returned $118,850 worth of shares to the company (3,773 units at $31.50), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Op. & Scientific Officer Miller Steve returned $34,454,794 worth of shares to the company (1,093,803 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Tierney David S returned $12,074,391 worth of shares to the company (383,314 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax liability)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Strategy Officer Sundaram Preethi returned $1,726,326 worth of shares to the company (54,804 units at $31.50), closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChairman of Board of Directors Mcenany Patrick J returned $131,404,108 worth of shares to the company (4,171,559 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERPresident and CEO Daly Richard J returned $8,544,879 worth of shares to the company (271,266 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Commercial Officer Del Carmen Jeffrey returned $451,616 worth of shares to the company (14,337 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Medical Officer Andrews William T. returned $72,734 worth of shares to the company (2,309 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Denkhaus Donald A returned $15,711,350 worth of shares to the company (498,773 units at $31.50), closing all direct ownership in the company (SEC Form 4) (withholding tax)4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERChief Financial Officer Kalb Michael Wayne returned $430,448 worth of shares to the company (13,665 units at $31.50), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- INSIDERDirector Harper Molly returned $116,361 worth of shares to the company (3,694 units at $31.50), closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
- SECSEC Form EFFECT filed by Catalyst Pharmaceuticals Inc.EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form EFFECT filed by Catalyst Pharmaceuticals Inc.EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form EFFECT filed by Catalyst Pharmaceuticals Inc.EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form EFFECT filed by Catalyst Pharmaceuticals Inc.EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form EFFECT filed by Catalyst Pharmaceuticals Inc.EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form S-8 POS filed by Catalyst Pharmaceuticals Inc.S-8 POS - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form S-8 POS filed by Catalyst Pharmaceuticals Inc.S-8 POS - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form S-8 POS filed by Catalyst Pharmaceuticals Inc.S-8 POS - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form S-8 POS filed by Catalyst Pharmaceuticals Inc.S-8 POS - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form S-8 POS filed by Catalyst Pharmaceuticals Inc.S-8 POS - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
- SECSEC Form S-8 POS filed by Catalyst Pharmaceuticals Inc.S-8 POS - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
CPRX FAQ
7 questionsWhat does Catalyst Pharmaceuticals Inc. do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3...Where does CPRX stock trade?
Catalyst Pharmaceuticals Inc. (CPRX) is listed on NASDAQ.What sector and industry is CPRX in?
Catalyst Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Catalyst Pharmaceuticals Inc. go public?
Catalyst Pharmaceuticals Inc. (CPRX) completed its IPO in 2006.What are analysts saying about CPRX?
Catalyst Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $2800.00 price target on 2025-02-04. Recent price targets range from $1200.00 to $3500.00.What companies are similar to CPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CPRX side-by-side with any of them on Quantisnow.How can I track CPRX on Quantisnow?
Quantisnow aggregates Catalyst Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CPRX to receive live email and push alerts on every new disclosure.